In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually ailment progression or perhaps the members are not able to tolerate the study drugs. Ubiquitin-relevant proteins that regulate the stability of key super enhancer-mediated proteins https://abbv-744-in-acute-myeloid14579.ttblogs.com/11546788/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets